PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.73%
Negative EBIT growth while TRAW is at 100.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-5.73%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-4.82%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-5.05%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-5.05%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3274.19%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-3274.19%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.86%
10Y OCF/share CAGR at 50-75% of TRAW's 77.68%. Martin Whitman might fear a structural deficiency in operational efficiency.
47.86%
Positive OCF/share growth while TRAW is negative. John Neff might see a comparative advantage in operational cash viability.
47.86%
Positive 3Y OCF/share CAGR while TRAW is negative. John Neff might see a big short-term edge in operational efficiency.
60.77%
Net income/share CAGR at 50-75% of TRAW's 98.31%. Martin Whitman might question if the firm’s product or cost base lags behind.
60.77%
Positive 5Y CAGR while TRAW is negative. John Neff might view this as a strong mid-term relative advantage.
60.77%
Positive short-term CAGR while TRAW is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.11%
Negative asset growth while TRAW invests at 81849.33%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.64%
We have a declining book value while TRAW shows 59775.48%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
8.65%
Debt growth of 8.65% while TRAW is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
6.08%
SG&A declining or stable vs. TRAW's 61301.60%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.